Bloomberg Law, December 7: Bloomberg Law news article describes the strong opposition to FDA’s plan to regulate lab-developed tests (LDTs). We explain why patients can’t trust the results of these diagnostic tests unless FDA makes sure they are accurate.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
FDA’s Janet Woodcock to retire early next year
STAT News, November 16, 2023: Principal Deputy FDA Commissioner Janet Woodcock will retire from the FDA in early 2024 after almost 40 years at the agency, many as a powerful and controversial leader. We explain how her legacy has tarnished the FDA’s reputation.
Read More »After Drug Trial Fizzles, Sarepta Still Seeks Broad Approval
Bloomberg News, November 1, 2023: Sarepta’s gene therapy Elevidys failed to confirm efficacy for Duchenne Muscular Dystrophy. Will FDA convert accelerated approval to full approval anyway? We explain why that would be ridiculous, but not impossible. But who will pay for an unproven treatment that costs $3.2 million per patient?
Read More »Are PIP rubber playgrounds safe for Kingston?
Kingston Wire, October 23, 2023: NCHR president Diana Zuckerman’s oped in the Kingston (NY) Wire explains the risks to children of lead and other toxic chemicals in PIP rubber playground surfaces and artificial turf in Kingston and other communities.
Read More »Experts fear FDA push to get neurological drugs to market faster shortchanges patients
Politico Pro, October 20, 2023: Politico news story explains that FDA’s accelerated approval of neurological drugs shortchanges patients who have lobbied for it because these very expensive drugs aren’t proven to work
Read More »